Citigroup
EDIT icon

Citigroup’s Editas Medicine EDIT Stock Holding History

Citigroup’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-99,700
Closed -$6.99M – 6534
2020
Q4 		$6.99M Buy
99,700
+43,300
+77% +$1.78M ﹤0.01% 1840
2020
Q3 		$1.58M Sell
56,400
-9,200
-14% -$300K ﹤0.01% 2875
2020
Q2 		$1.94M Sell
65,600
-12,200
-16% -$319K ﹤0.01% 2845
2020
Q1 		$1.54M Buy
77,800
+2,000
+3% +$50.4K ﹤0.01% 2743
2019
Q4 		$2.24M Buy
75,800
+20,300
+37% +$507K ﹤0.01% 2846
2019
Q3 		$1.26M Buy
55,500
+6,100
+12% +$151K ﹤0.01% 3377
2019
Q2 		$1.22M Buy
49,400
+22,700
+85% +$542K ﹤0.01% 3396
2019
Q1 		$653K Buy
26,700
+6,900
+35% +$156K ﹤0.01% 3891
2018
Q4 		$450K Buy
19,800
+5,600
+39% +$152K ﹤0.01% 4241
2018
Q3 		$452K Buy
14,200
+8,100
+133% +$262K ﹤0.01% 4406
2018
Q2 		$219K Buy
6,100
+4,800
+369% +$170K ﹤0.01% 4978
2018
Q1 		$43K Buy
+1,300
New +$46.3K ﹤0.01% 6269

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citigroup's EDIT Position: Q2 2026 in Review

Citigroup increased its Editas Medicine (EDIT) stake by 749% in Q2 2026, buying an estimated $160K and bringing the position to 61,964 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #4339.

Citigroup first reported a position in EDIT in Q1 2016 and has held it in 42 quarters since. The position peaked at $8.12M in Q2 2021. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Citigroup held 61,964 shares of Editas Medicine worth $201K as of Q2 2026.
  • Citigroup bought 54,666 Editas Medicine shares in Q2 2026, an estimated $160K.
  • Editas Medicine made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4339 holding.
  • Citigroup first reported a position in Editas Medicine in Q1 2016 and has held it in 42 quarters since.
  • Citigroup's Editas Medicine position peaked at $8.12M in Q2 2021.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.